双氯芬酸联合舌下硝酸盐预防内镜逆行胰胆管造影术后胰腺炎优于单用双氯芬酸
在日本12个内镜中心开展的前瞻性优效性随机试验中,患者被分为双氯芬酸单用组(n=442)和双氯芬酸联合舌下硝酸异山梨酯组(n=444),主要终点为术后胰腺炎发生率。联合组发生25例(5.6%),单用组发生42例(9.5%),相对风险0.59(95%CI 0.37-0.95;P=.03)。
要点
- 联合组术后胰腺炎发生率为5.6%,双氯芬酸单用组为9.5%,相对风险0.59(95%CI 0.37-0.95;P=.03)。
- 联合组中重度胰腺炎发生4例(0.9%),单用组10例(2.3%),相对风险0.12(95%CI 0.13-1.26;P=.12)。
- 未发生与追加舌下硝酸盐相关的严重不良事件。
核心结论
- 在随机对照试验中,直肠双氯芬酸联合舌下硝酸盐预防较单用双氯芬酸栓剂显著降低术后胰腺炎总体发生率。
研究设计与样本
- 前瞻性优效性随机试验,2015年3月至2018年5月在日本12个内镜中心纳入接受内镜逆行胰胆管造影术的患者。
- 患者随机分为双氯芬酸单用组(n=442,术后15分钟内给予双氯芬酸栓剂50 mg)和联合组(n=444,术前5分钟给予舌下硝酸异山梨酯5 mg联合双氯芬酸栓剂50 mg)。
- 主要终点为术后胰腺炎的发生。
主要发现
- 联合组术后胰腺炎发生25例(5.6%),双氯芬酸单用组发生42例(9.5%)(相对风险0.59;95%CI 0.37-0.95;P=.03)。
- 联合组中重度胰腺炎发生4例(0.9%),双氯芬酸单用组发生10例(2.3%)(相对风险0.12;95%CI 0.13-1.26;P=.12)。
- 未发生与追加舌下硝酸盐相关的严重不良事件。
关键数值与推荐
- 双氯芬酸单用组:术后15分钟内给予双氯芬酸栓剂50 mg。
- 联合组:术前5分钟给予舌下硝酸异山梨酯5 mg,术后15分钟内给予双氯芬酸栓剂50 mg。
- 主要终点术后胰腺炎:联合组25例(5.6%)vs 双氯芬酸单用组42例(9.5%),相对风险0.59(95%CI 0.37-0.95;P=.03)。
- 中重度胰腺炎:联合组4例(0.9%)vs 双氯芬酸单用组10例(2.3%),相对风险0.12(95%CI 0.13-1.26;P=.12)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Acute pancreatitis is a major adverse event of endoscopic retrograde cholangiopancreatography (ERCP). Rectal administration of nonsteroidal anti-inflammatory drugs (NSAIDs) decreases the incidence of post-ERCP pancreatitis (PEP). Little is known about the combined effects of sublingual nitrate and NSAIDs. We performed a randomized trial to assess whether the combination of NSAIDs and sublingual nitrate is more effective than NSAIDs alone in preventing PEP. METHODS: In a prospective superiority trial, eligible patients underwent ERCP at 12 endoscopic units in Japan, from March 2015 through May 2018. Patients were randomly assigned to groups given diclofenac suppositories (50 mg) within 15 minutes after the endoscopic procedure alone (diclofenac-alone group, n = 442) or in combination with sublingual isosorbide dinitrate (5 mg) 5 minutes before the endoscopic procedure (combination group, n = 444). The primary endpoint was the occurrence of PEP. RESULTS: PEP developed in 25 patients in the combination group (5.6%), and in 42 patients in the diclofenac-alone group (9.5%) (relative risk 0.59; 95% confidence interval 0.37-0.95; P = .03). Moderate to severe pancreatitis developed in 4 patients (0.9%) in the combination group, and 10 patients (2.3%) in the diclofenac-alone group (relative risk 0.12; 95% confidence interval 0.13-1.26; P = .12). There was no serious adverse event related to the additional administration of sublingual nitrate. CONCLUSIONS: In a randomized controlled trial, we found that prophylaxis with rectal diclofenac and sublingual nitrate significantly reduces the overall incidence of PEP compared with diclofenac suppository alone. ClinicalTrials.gov, no: UMIN 000016274.
引用
- Tomoda T, Kato H, Ueki T, et al. Combination of Diclofenac and Sublingual Nitrates Is Superior to Diclofenac Alone in Preventing Pancreatitis After Endoscopic Retrograde Cholangiopancreatography. Gastroenterology. 2019. PMID: 30772342. doi:10.1053/j.gastro.2019.01.267
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。